Pediatric Cancers

Latest News

Administering pegylated asparaginase continuously to pediatric patients with acute lymphoblastic leukemia appears to be safe without compromising the efficacy of treatment.
Continuous PEGasparaginase Prevents Antibody Formation in Pediatric ALL

February 12th 2024

Administering pegylated asparaginase continuously to pediatric patients with acute lymphoblastic leukemia appears to be safe without compromising the efficacy of treatment.

FDA initiatives such as the Food and Drug Omnibus Reform Act will set goals and specify measures for improving representation in pediatric cancer clinical studies.
Hispanic Population Appears Underrepresented in Pediatric Cancer Trials

January 31st 2024

Investigators report that prediabetes may prove to be a target for intervention to decrease morbidity and mortality in survivors of pediatric cancer.
Risk of Prediabetes/Complications Seen in Adult Pediatric Cancer Survivors

January 6th 2024

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results in both Study 3b and Study ANBL0032.
Eflornithine Is Approved by the FDA for High-Risk Neuroblastoma

December 13th 2023

Patients who are under the age of 17 with invasive mucormycosis or invasive aspergillosis, which is an AE of leukemia, can now receive isavuconazonium sulfate following FDA approval
FDA Approves Isavuconazonium Sulfate for Pediatric Fungal Infections

December 8th 2023

Video Interviews

More News